1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jinhe Biotechnology Co., Ltd. Class A

Jinhe Biotechnology Co., Ltd. Class A

SSZSE:002688
4.87
CNY
+0.04
(+0.83%)
3.56BMarket Cap
Oct 30Next Earn
Jinhe Biotechnology Co., Ltd. Class A
SZSE:002688
(Shenzhen Stock Exchange)

Recent

price

4.87

P/E

ratio

- -

div

yld

3.35%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.45
1.77
1.65
1.38
1.52
2.27
2.37
2.29
2.59
2.79
2.78
2.99
2.72
2.79
3.06
3.69
- -
Revenue per Share
0.13
0.19
0.19
0.17
0.14
0.19
0.26
0.17
0.26
0.29
0.18
0.14
0.1
0.11
0.13
0.04
- -
Basic EPS, GAAP
0.15
0.16
0.12
-0.02
-0.74
0.13
0.26
-0.27
-0.08
0.16
0.08
-0.33
-0.36
-0.33
0.18
0.19
- -
Free Cash Flow per Basic Share
0.04
0.04
0.03
0.1
0.06
0.07
0.16
0.21
0.1
0.35
0.34
0.15
0.05
0.19
0.21
0.19
0.16
Dividend per Share
0.59
0.79
1.59
1.65
1.75
1.9
2.36
2.4
2.64
2.64
2.54
3.12
2.85
2.88
2.91
2.89
2.95
Book Value per Share
0.52
0.71
1.53
1.6
1.26
1.37
0.67
0.76
0.94
0.97
0.98
1.83
1.55
1.29
1.39
1.63
1.73
Tangible Book Value per Share
408
407
467
538
551
551
631
638
629
638
652
696
780
780
774
781
760
Basic Weighted Avg Shares
590
721
770
741
840
1,250
1,496
1,458
1,629
1,782
1,815
2,078
2,123
2,174
2,371
2,878
- -
Sales/Revenue/Turnover
13.76
15.35
14.8
15.24
10.41
11.54
14.11
15.85
14.67
14.07
12.55
10.91
7.75
8.52
12.18
11.74
- -
Operating Margin (%)
34
38
39
37
42
54
56
72
86
99
120
132
156
179
194
239
- -
Depreciation Expense
53
77
90
90
77
105
164
108
164
185
117
94
76
86
100
28
- -
Net Income, GAAP
17.09
15.87
16.98
16.21
15.01
9.95
19.08
25.33
15.48
13.57
1.22
14.57
0.61
6.96
13.77
128.06
- -
Effective Tax Rate (%)
8.94
10.74
11.63
12.2
9.19
8.37
10.97
7.44
10.05
10.38
6.47
4.52
3.56
3.98
4.23
0.96
- -
Profit Margin (%)
-34
10
548
475
539
-10
336
225
213
95
-134
486
82
-218
159
256
336
Working Capital
50
- -
- -
- -
318
- -
206
264
265
267
136
87
304
524
985
1,007
982
LT Debt
255
334
864
900
956
1,055
1,584
1,637
1,779
1,807
1,750
2,696
2,425
2,517
2,500
2,443
2,487
Total Equity
10.03
13.03
10.88
9.67
6.16
7.15
8.92
4.73
6.04
5.08
4.19
3.51
3.12
2.21
1.77
-0.25
- -
Return on Invested Capital (%)
12.85
16.23
13.41
10
6.68
7.78
9.28
5.85
7.46
7.78
5.09
3.36
2.05
3.02
3.67
0.88
- -
Return on Capital (%)
24.7
27.41
15.09
10.25
8.34
10.54
12.97
7.17
10.21
11.02
7.12
4.64
3.25
3.87
4.46
1.23
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,313
1,431
1,382
LT Borrowings
992
1,127
967
LT Finance Leases
15
14
14
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
772
770
770
Market Capitalization
4,591
4,471
3,555

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,058
2,395
2,229
Cash, Cash Equivalents & STI
620
839
701
Accounts Receivable, Net
535
590
551
Inventories
668
725
775
Total Current Liabilities
1,802
1,845
1,894
Payables & Accruals
- -
- -
- -
ST Debt
1,313
1,431
1,382
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.55%
8.97%
-2.26%
Free Cash Flow
-114.67%
-131.37%
9.15%
Net Income, GAAP
-3.14%
-16.34%
-72.5%
Sales/Revenue/Turnover
8.96%
9.91%
21.41%
Total Cash Common Dividend
52.27%
30.5%
-8.15%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
519
546
592
713
2,371
2025
625
765
- -
842
2,878
2026
742
706
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.06
0.03
-0.02
0.13
2025
0.07
0.12
- -
-0.15
0.04
2026
0.08
0.09
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.13
0.03
0.03
0.21
2025
0.02
0.12
- -
0.02
0.19
2026
0.02
0.12
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jinhe Biotechnology Co. Ltd. (002688.SZ) is a China-based company principally engaged in the production and sale of veterinary medicines and animal health products. The company manufactures core products including chlortetracycline feed grade, a broad-spectrum antimicrobial for treating poultry and livestock diseases such as white dysentery, enteritis, pneumonia, typhoid, paratyphoid and cholera; chlortetracycline hydrochloride for bacterial infections including pullorum disease, swine enteritis, paratyphoid and cholera; salinomycin powder and granule for eimeria control in chickens and gram-positive bacteria inhibition; as well as quinomycin premix, oxytetracycline and other feed additives. Founded in 1990 and headquartered in Tuoketuo County, Hohhot, Inner Mongolia, China, with additional operations in Dalian, the company maintains advanced fermentation facilities boasting a 12,194 cubic meter capacity and annual output exceeding 45,000-55,000 metric tons, exporting over 70% of production to the United States, Southeast Asia, Latin America, Europe and other regions; it serves partners such as Zoetis (formerly Pfizer). Jinhe listed on the Shenzhen Stock Exchange in 2012, passed US FDA inspections eight times most recently in 2023, and holds certifications including China GMP, Europe COS and Japan FMA; in 2014 its wholly owned US subsidiary Pharmgate LLC acquired Pennfield Oil Company to expand into the American animal health market. Recent developments include plans announced in 2025 to raise up to 300 million yuan via simplified private placement of A-shares to no more than 35 targets for sewage treatment expansion, water recycling upgrades, new grain storage facilities and working capital supplementation, alongside approval of a final 2024 cash dividend payable in June 2025.